针对慢性乙型肝炎的聚乙二醇干扰素的预测：基于医院现实

StephenW

Sci Rep. 2016 Jul 12;6:29605. doi: 10.1038/srep29605.
Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis.Wang YC1, Yang SS2, Su CW1, Wang YJ3, Lee KC1, Huo TI1,4, Lin HC1, Huang YH1,5.
Author information

• 1Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
• 2Liver Center, Cathay General Hospital Medical Center, Taipei, Taiwan.
• 3Health Care Center, Taipei Veterans General Hospital, Taipei, Taiwan.
• 4Institute of Pharmacology, National Yang-Ming University School of Medicine, Taipei, Taiwan.
• 5Institute of Clinical Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan.
  

AbstractInformation on the efficacy of pegylated interferon (PEG-IFN) treatment of chronic hepatitis B (CHB) patients and predictors of the response based on real-world data is limited. Consecutive 201 patients who underwent PEG-IFN treatment for CHB were reviewed. A virological response (VR) was defined as a serum HBV DNA of <2000 IU/mL, and a combined response (CR) was defined a VR accompanied by serological response for hepatitis B e antigen (HBeAg)-positive CHB. For HBeAg-positive CHB patients, the HBeAg seroconversion rate and CR rate were 30.5% and 21.2% at 48 weeks after end of treatment (EOT), respectively. Baseline alanine aminotransferase (ALT) level was associated with HBeAg seroconversion, while baseline hepatitis B s antigen (HBsAg) levels of <250 IU/mL and HBV DNA <2.5 × 107 IU/mL were strongly associated with sustained off-treatment CR. For HBeAg-negative CHB, the VR rates were 85.5%, and 27.7% at EOT, and 48 weeks after EOT, respectively; a baseline HBsAg <1,250 IU/mL was associated with sustained off-treatment VR. PEG-IFN treatment has durable HBeAg seroconversion in HBeAg-positive CHB, but results in a high risk of relapse among HBeAg-negative CHB patients. Pre-treatment HBsAg level is an important predictor of VR in CHB patients undergoing PEG-IFN treatment.


PMID:27405043DOI:10.1038/srep29605

StephenW

。科学众议员2016年7月12日; 6：29605。 DOI：10.1038 / srep29605。
针对慢性乙型肝炎的聚乙二醇干扰素的预测：基于医院现实世界的分析。
王YC1，杨SS2，苏CW1，王YJ3，李KC1，霍TI1,4，盐酸林，黄YH1,5。
作者信息

    胃肠病学和肝病，内科，台北荣民总医院，台北，台湾1区。
    2Liver中心，国泰医院医疗中心，台北，台湾。
    3Health护理中心，台北荣民总医院，台北，台湾。
    药理4Institute，医药，台北，台湾国立阳明大学学院。
    临床医学5Institute，医药，台北，台湾国立阳明大学学院。

抽象

基于真实世界数据聚乙二醇干扰素（PEG-IFN）治疗慢性乙型肝炎（CHB）的患者和响应预测的疗效信息是有限的。连续201例谁接受PEG-IFN治疗慢性乙型肝炎进行了审查。一个病毒学应答（VR）定义为<2,000 IU / mL的血清HBV DNA，并组合响应（CR）定义一个VR伴有乙肝e抗原（HBeAg）阳性慢性乙肝血清学应答。对于HBeAg阳性慢性乙型肝炎患者中，HBeAg血清转换率和CR率分别为30.5％和分别在治疗结束（EOT）后48周，21.2％。基线丙氨酸转氨酶（ALT）水平与血清​​转换相关联，而基线肝炎BS抗原（HBsAg）的水平<250国际单位/毫升和HBV DNA <2.5×107 IU / mL的强烈持续关断处理的CR相关联。对于HBeAg阴性，在VR率分别为85.5％，并在EOT 27.7％，和48周后的EOT，分别;基准的HBsAg <1250 IU / mL的与持续关治疗VR相关。 PEG-IFN治疗在HBeAg阳性CHB持久的HBeAg血清学转换，但复发的HBeAg阴性慢性乙肝患者中高风险的结果。前处理的HBsAg水平VR的慢性乙型肝炎患者接受PEG-IFN治疗的重要预测指标。

结论：
    27405043
DOI：
    10.1038 / srep29605